Synthesis and biological evaluation of novel (E)-N'-benzylidene hydrazides as novel c-Met inhibitors through fragment based virtual screening

References

• Ma PC, Maulik G, Christensen J, Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 2003;22:309–25.
   PubMed Web of Science ®Google Scholar
• Puccini A, Marín-Ramos NI, Bergamo F, et al. Safety and tolerability of c-MET inhibitors in cancer. Drug Saf 2019;42:211–33.
   PubMed Web of Science ®Google Scholar
• Abstracts from the 2009 Joint Meeting of the Society for Neuro-Oncology (SNO) and the American Association of Neurological Surgeons/Congress of Neurological Surgeons (AANS/CNS) Section on Tumors. Neuro Oncol 2009;11:563–699.
   Web of Science ®Google Scholar
• Matsumura A, Kubota T, Taiyoh H, et al. HGF regulates VEGF expression via the c-Met receptor downstream pathways, PI3K/Akt, MAPK and STAT3, in CT26 murine cells. Int J Oncol 2013;42:535–42.
   PubMed Web of Science ®Google Scholar
• Marquardt JU, Seo D, Gómez-Quiroz LE, et al. Loss of c-Met accelerates development of liver fibrosis in response to CCl 4 exposure through deregulation of multiple molecular pathways. Biochim Biophys Acta – Mol Basis Dis 2012;1822:942–51.
   Web of Science ®Google Scholar
• Dulak AM, Gubish CT, Stabile LP, et al. HGF-independent potentiation of EGFR action by c-Met. Oncogene 2011;30:3625–35.
   PubMed Web of Science ®Google Scholar
• Velpula KK, Dasari VR, Asuthkar S, et al. EGFR and c-Met cross talk in glioblastoma and its regulation by human cord blood stem cells. Transl Oncol 2012;5:379–92.
   PubMed Web of Science ®Google Scholar
• Ray A, Dhar S, Ray BK. Abstract 5278: suppression of angiogenic potential of breast cancer by the inhibition of SAF-1 transcription factor activity. Cancer Res 2012;72:Abstract nr 5278.
   PubMed Web of Science ®Google Scholar
• Chen HM, Tsai CH, Hung WC. Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling. Oncotarget 2015;6:14940–52.
   PubMedGoogle Scholar
• Sennino B, Ishiguro-Oonuma T, Wei Y, et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov 2012;2:270–87.
   PubMed Web of Science ®Google Scholar
• Zhang J, Jiang X, Jiang Y, et al. Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs. Eur J Med Chem 2016;108:495–504.
   PubMed Web of Science ®Google Scholar
• De AX, Liu H, Xu ZL, et al. Discovery of potent 1H-imidazo[4,5-b]pyridine-based c-Met kinase inhibitors via mechanism-directed structural optimization. Bioorg Med Chem Lett 2015;25:708–16.
   PubMed Web of Science ®Google Scholar
• El-Wakil MH, Ashour HM, Saudi MN, et al. Target identification, lead optimization and antitumor evaluation of some new 1,2,4-triazines as c-Met kinase inhibitors. Bioorg Chem 2017;73:154–69.
   PubMed Web of Science ®Google Scholar
• Zhan Z, Ai J, Liu Q, et al. Discovery of anilinopyrimidines as dual inhibitors of c-Met and VEGFR-2: synthesis, SAR, and cellular activity. ACS Med Chem Lett 2014;5:673–8.
   PubMed Web of Science ®Google Scholar
• Wei D, Fan H, Zheng K, et al. Synthesis and anti-tumor activity of [1,4] dioxino [2,3-f] quinazoline derivatives as dual inhibitors of c-Met and VEGFR-2. Bioorg Chem 2019;88:102916.
   PubMed Web of Science ®Google Scholar
• Hughes VS, Siemann DW. Failures in preclinical and clinical trials of c-Met inhibitors: evaluation of pathway activity as a promising selection criterion. Oncotarget 2019;10:184–97.
   PubMedGoogle Scholar
• Liang J, Li X, Yang S, et al. Design, synthesis and biological evaluation of uracil derivatives as novel VEGFR-2 inhibitors. Curr Pharm Des 2018;24:734–40.
   PubMed Web of Science ®Google Scholar
• Zhang QW, Ye ZD, Shen C, et al. Synthesis of novel 6,7-dimethoxy-4-anilinoquinolines as potent c-Met inhibitors. J Enzyme Inhib Med Chem 2019;34:124–33.
   PubMed Web of Science ®Google Scholar
• Scott DE, Coyne AG, Hudson SA, Abell C. Fragment-based approaches in drug discovery and chemical biology. Biochemistry 2012;51:4990–5003.
   PubMed Web of Science ®Google Scholar
• Murray CW, Verdonk ML, Rees DC. Experiences in fragment-based drug discovery. Trends Pharmacol Sci 2012;33:224–32.
   PubMed Web of Science ®Google Scholar
• Lawrence HR, Mahajan K, Luo Y, et al. Development of novel ACK1/TNK2 inhibitors using a fragment-based approach. J Med Chem 2015;58:2746–63.
   PubMed Web of Science ®Google Scholar
• Qian F, Engst S, Yamaguchi K, et al. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res 2009;69:8009–16.
   PubMed Web of Science ®Google Scholar
• Oguro Y, Miyamoto N, Okada K, et al. Design, synthesis, and evaluation of 5-methyl-4-phenoxy-5H-pyrrolo[3,2-d] pyrimidine derivatives: novel VEGFR2 kinase inhibitors binding to inactive kinase conformation. Bioorg Med Chem 2010;69:8009–16.
   Google Scholar
• Wu PK, Park JI. MEK1/2 inhibitors: molecular activity and resistance mechanisms. Semin Oncol 2015;42:849–62.
   PubMed Web of Science ®Google Scholar
• Breen ME, Soellner MB. Small molecule substrate phosphorylation site inhibitors of protein kinases: approaches and challenges. ACS Chem Biol 2015;10:175–89.
   PubMed Web of Science ®Google Scholar
• Wu J, Huang C, Wang J, et al. Separation, interconversion, and insecticidal activity of the cis- and trans-isomers of novel hydrazone derivatives. J Sep Sci 2013;36:602–8.
   PubMed Web of Science ®Google Scholar
• Alam MS, Lee DU. Syntheses, crystal structure, Hirshfeld surfaces, fluorescence properties, and DFT analysis of benzoic acid hydrazone Schiff bases. Spectrochim Acta – Part A Mol Biomol Spectrosc 2015;145:563–74.
   PubMed Web of Science ®Google Scholar